Managing Uncertainty in Healthcare

We help innovators and payers quantify and optimize risk-sharing to improve market access.

What We Do

We predict and prove the value of new medicines.

Estimate Supportable Prices for Innovators

Identify and demonstrate the value and effectiveness of treatments in the real world to support pricing strategies

Predict the Commercial Value for Investors and Biopharmaceutical Companies

Predict lifetime revenues for late-stage products not yet on the market, leveraging predictions on their effectiveness and marketplace characteristics

Optimize Trial Design and Evidence Development

Calculate financial ROI for alternative trial design and evidence-generation strategies

Design and Implement Value-Based Contracts

Evaluate the financial returns on alternative contract designs and provide supportable methodologies for revenue recognition

About Us

We were founded by three health economists — bringing together decades of academic and industry experience — to unlock financial innovation in the way new medicines are delivered to patients. Our growing, world-class team is composed of economists, data scientists, software engineers, finance professionals, and cutting-edge academic experts.

Managing Risk and Uncertainty

The Challenge: Predicting and Proving the Value of New Medicines is Hard

Pricing, investment, and evidence-generation decisions are often made before real-world evidence exists. Trial data are often too limited to support robust predictions of real-world value.  Innovators and investors must speculate about the real-world value when making investments in research, development, or acquisition.

Our Approach

Our proprietary algorithms combine clinical trial and real-world data to enable life science innovators, payers and clinicians to predict outcomes and build access strategies around the anticipated value, uptake, and durability of new treatments in the real world.

Latest News

Check Out Our Latest White Paper

Meeting the Analytic Challenges of Value-Based Agreements in Life Sciences

Read More >

Our Latest Publications

Value in Health Journal

“Health Technology Assessment with Diminishing Returns to Health: The Generalized Risk-Adjusted Cost Effectiveness (GRACE) Approach.”

Read More >